News Biosergen AB

Equities

BIOSGN

SE0016013460

Market Closed - Nasdaq Stockholm Other stock markets 09:55:44 2024-05-15 am EDT			5-day change	1st Jan Change
0.3 ^SEK	-2.60%		-12.28%	-65.91%

Apr. 09	Biosergen to Issue New Units as Compensation Under Rights Issue	MT
Mar. 27	Biosergen Raises SEK26.4 Million via Rights Issue	MT

Summary

Unlock all the news on all businesses: Never miss an investment opportunity again!

100% Free Registration

BioStock: Biosergen's CEO - "this is a global health threat and it needs attention"	May. 14	AQ
Biosergen publishes 2023 annual report	May. 10	AQ
Conversion of paid subscribed units and first day of trading with warrants of series TO3	Apr. 16	AQ
Biosergen to Issue New Units as Compensation Under Rights Issue	Apr. 09	MT
Biosergen resolves on a directed issue to underwriters in connection with the completed rights issue	Apr. 09	AQ
Biosergen Raises SEK26.4 Million via Rights Issue	Mar. 27	MT
Biosergen announces the outcome in the rights issue	Mar. 26	AQ
BioStock Investor Pitch: Biosergen	Mar. 18	AQ
Members of the board of directors and management subscribe in ongoing rights issue	Mar. 15	AQ
Research update Biosergen: Rights issue to fund crucial step for lead project	Mar. 13	AQ
BioStock: Rights issue to give Biosergen first in-human efficacy data	Mar. 12	AQ
BioStock: Biosergen attacks invisible threat of fungal infections	Mar. 08	AQ
Carlsquare Equity Research interview with Biosergen	Mar. 07	AQ
Biosergen CEO to BioStock: "Positive data give us a strong value proposition"	Mar. 07	AQ
Biosergen publishes prospectus due to rights issue of units	Mar. 05	AQ
Bulletin from the extraordinary general meeting in Biosergen AB (publ)	Mar. 01	AQ
Biosergen publishes interim report for fourth quarter 2023	Feb. 29	AQ
Biosergen AB Reports Earnings Results for the Full Year Ended December 31, 2023	Feb. 29	CI
Norway's Biosergen Secures Indian Regulatory Approval for Clinical Trial of Fungal Infections Therapy	Feb. 12	MT
Biosergen receives regulatory approval to test lead candidate BSG005 in patients with invasive fungal infection.	Feb. 12	AQ

No results for this search

All News Analyst Reco. Highlights Insiders Transcripts Press Releases Official Publications Other languages Trading Ideas MarketScreener Editorial Features MarketScreener Strategies

News Biosergen AB

Equities

BIOSGN

SE0016013460

Summary

Filters